Article
Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice.
Science (New York, N.Y.) - 19 Jul 2002
Millar Catherine B, Guy Jacky, Sansom Owen J, Selfridge Jim, MacDougall Eilidh, Hendrich Brian, Keightley Peter D, Bishop Stefan M, Clarke Alan R, Bird Adrian
Abstract excerpt
The mammalian protein MBD4 contains a methyl-CpG binding domain and can enzymatically remove thymine (T) or uracil (U) from a mismatched CpG site in vitro. These properties suggest that MBD4 might function in vivo to minimize the mutability of 5-methylcytosine by removing its deamination product from DNA. We tested this hypothesis by analyzing Mbd4-/- mice and found that the frequency of of C --> T transitions at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
